Pyridostigmine (bromide)

• UNSPSC Description:

  Pyridostigmine bromide is an orally active cholinesterase (ChE) inhibitor that can be used in cardiovascular disease research[1][2][3][4][5].

• Target Antigen:

  Cholinesterase (ChE)

• Type:

  Reference compound

• Related Pathways:

  Neuronal Signaling

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/pyridostigmine-bromide.html

• Purity:

  99.93

• Solubility:

  DMSO : 50 mg/mL (ultrasonic)|H2O : 8.8 mg/mL (ultrasonic;warming)

• Smiles:

  C[N+]1=CC=CC(OC(N(C)C)=O)=C1.[Br-]

• Molecular Weight:

  261.12

• References & Citations:

  [1]Gales BJ, et al. Pyridostigmine in the treatment of orthostatic intolerance. Ann Pharmacother. 2007 Feb;41(2):314-8. Epub 2007 Feb 6.|[2]Kanjwal K, et al. Pyridostigmine in the treatment of postural orthostatic tachycardia: a single-center experience. Pacing Clin Electrophysiol. 2011 Jun;34(6):750-5.|[3]Bernatova I, et al. Effect of chronic pyridostigmine bromide treatment on cardiovascular and behavioral parameters in mice[J]. Pharmacology Biochemistry and Behavior, 2003, 74(4): 901-907.|[4]de Cuba MB, et al. Effects of cholinergic stimulation with pyridostigmine bromide on chronic chagasic cardiomyopathic mice. Mediators Inflamm. 2014;2014:475946.|[5]Azzolin VF, et al. Effects of Pyridostigmine bromide on SH-SY5Y cells: An in vitro neuroblastoma neurotoxicity model. Mutat Res Genet Toxicol Environ Mutagen. 2017 Nov;823:1-10.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, stored under nitrogen)

• Clinical Information:

  Launched

• CAS Number:

  101-26-8